Grade: Pharmaceutical Grade

Factory Location: *

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Sample Provided: no

Payment Terms: L/C

Abemaciclib is an oral cyclin-dependent kinase CDK4/6 inhibitor. In HR +, HER2-breast cancer cells, CDK4 and CDK6 promote phosphorylation of retinoblastoma protein (retinoblastomapChemicalbookrotein, Rb) and promote cell cycle progression and cell proliferation. Abemaciclib inhibits phosphorylation of Rb and blocks cell progression from the G1 phase of the cell cycle to the S phase, resulting in cell aging and apoptosis